Current state of biomarker development for clinical application in epithelial ovarian cancer.
about
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesIn 2014, can we do better than CA125 in the early detection of ovarian cancer?Adverse events associated with complementary and alternative medicine use in ovarian cancer patientsMALDI Imaging Mass Spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis.Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials.Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancerProgranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levelsComparison of candidate serologic markers for type I and type II ovarian cancerNovel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.Comparison of specific ovarian tumor markers by elecsys analyzer 2010Epigenomics of ovarian cancer and its chemoprevention.Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective StudyThe C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesisSerum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.Tumor markers for early detection of ovarian cancer.New players in ovarian cancer.Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.Role of epigenomics in ovarian and endometrial cancers.Ovarian cancer molecular pathology.An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors.Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian CancerGenomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.Evaluation of serum mesothelin in malignant and benign ovarian masses.Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.
P2860
Q24634978-6CD30F2F-875D-46CB-B2B7-494516A038DEQ26825152-CD76D15B-8748-4795-B3C9-294B41B79E91Q27022402-F0D85B53-FDD6-4776-BFBD-1E013467AE83Q30476935-10ABC298-B09D-4BB1-A16F-026DAD4D643AQ33850475-1833A76F-3FC5-4E31-911E-424673322949Q33944027-FF461577-6AC8-4FE6-A67C-BA972418756CQ34384802-1E612FBC-432B-4AAC-B4DF-F0AD6BE1D6F4Q35067319-40A585CF-B98A-4848-9A8C-F77690C898C7Q35154077-8C3DC3F2-B783-409F-BE33-F80ED26BB0F7Q35298842-24E5D004-2D97-4634-A7BB-76A7BF7C9CC9Q35601405-40D0071F-194E-456C-8E95-053CDA6562FFQ35711392-E20782EE-21B1-4414-A42F-84AD365FE6D1Q36201267-2AA52146-285E-4FB5-95AF-D3ED39310884Q36229421-750C0E52-63B8-4F10-8D32-D7C11DD25FEDQ37529387-A712EA11-88F8-4C42-9BFB-54F7FC379AFAQ37703442-FFA8015B-85EF-4289-B05B-7D68F834D79CQ37789033-629F7625-F8AA-40B1-AF2F-92A05D8E6A1CQ37837735-7D916A60-A81F-4491-B4AE-0B8E5D8B4D42Q37837982-DB136146-8332-4BB9-8B6C-F1A4D5E6C6FFQ37961734-600B02D1-2A99-4382-89FE-C99377768C1EQ38021356-24CF00C6-3E18-4E7B-91BA-650C0AF2791AQ38385143-0451177A-3E5E-46CC-9A2D-06217271A170Q38716321-BAA5417E-781E-469E-A7F2-7F0A15ADE88AQ38957886-21797147-42A9-4B0D-8A98-6EE5C3979CA0Q41381707-4C067CCE-026B-468F-B325-1787E3F16A21Q41615733-8F41E023-66E5-44BB-AAF6-88FB5157B8A4Q45152682-873ED5D3-17E9-442F-AE34-A7B99CA325F6Q46245510-6BF1C3D7-4BD6-471C-B4DB-C3ACDC5DC755Q51351089-EE24D2E5-0210-465C-B03B-C0779F2851DF
P2860
Current state of biomarker development for clinical application in epithelial ovarian cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Current state of biomarker dev ...... in epithelial ovarian cancer.
@ast
Current state of biomarker dev ...... in epithelial ovarian cancer.
@en
type
label
Current state of biomarker dev ...... in epithelial ovarian cancer.
@ast
Current state of biomarker dev ...... in epithelial ovarian cancer.
@en
prefLabel
Current state of biomarker dev ...... in epithelial ovarian cancer.
@ast
Current state of biomarker dev ...... in epithelial ovarian cancer.
@en
P2093
P2860
P1433
P1476
Current state of biomarker dev ...... in epithelial ovarian cancer.
@en
P2093
Richard G Moore
Robert C Bast
Shannon MacLaughlan
P2860
P304
P356
10.1016/J.YGYNO.2009.09.041
P407
P577
2009-10-31T00:00:00Z